Quantum Discovery
Quantum Discovery Labs is a technology based drug discovery company. We develop a unique computational drug discovery platform (QUANTUM), provide drug discovery services, and pursue our own in-house drug discovery projects searching for novel compounds with anti-bacterial, anti-viral and anti-cancer efficacy.
Quantum@linkedin.com
Contacts: office@q-pharm.com or comment any post on the site. You are welcome!
Quantum on Google+
drug design Archive
-
![The manuscript entitled “” by the Quantum Team has been accepted to PLoS Currents Influenza. The reference:
Fedichev, Peter; Timakhov, Roman; Pyrkov, Tim; Getmantsev, Evgeny; Vinnik, Andrey. Structure-based drug design of [...]](http://q-pharm.com/wp-content/uploads/2011/08/f66forarticle-115x115.jpg "Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo")
Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo
Posted on August 9, 2011 | No CommentsThe manuscript entitled “” by the Quantum Team has been accepted to PLoS Currents Influenza. The reference: Fedichev, Peter; Timakhov, Roman; Pyrkov, Tim; Getmantsev, Evgeny; Vinnik, Andrey. Structure-based drug design of [...] -
![A key issue in the development of novel HIV drugs is their ability to inhibit the replication of genetically diverse isolates, especially those isolates from the most globally prevalent subtypes, [...]](http://q-pharm.com/wp-content/uploads/2011/06/variousvirustypes.png "New MA/p17 matrix protein inhibitors display broad antiviral activity against multiple subtypes of HIV-1")
New MA/p17 matrix protein inhibitors display broad antiviral activity against multiple subtypes of HIV-1
Posted on June 21, 2011 | No CommentsA key issue in the development of novel HIV drugs is their ability to inhibit the replication of genetically diverse isolates, especially those isolates from the most globally prevalent subtypes, [...] -
![We have recently reported a discovery of novel potent inhibitors of influenza M1 matrix protein. The matrix protein structurally forms the protein envelope and has no close human analogues. That’s [...]](http://q-pharm.com/wp-content/uploads/2011/04/chart_1.png "Influenza matrix M1 protein inhibitors show promising in-vivo efficacy")
Influenza matrix M1 protein inhibitors show promising in-vivo efficacy
Posted on April 10, 2011 | 1 CommentWe have recently reported a discovery of novel potent inhibitors of influenza M1 matrix protein. The matrix protein structurally forms the protein envelope and has no close human analogues. That’s [...] -
![Quantum Free energy calculation software in combination with the docking tools and clustering tools to “zip” the amount of work required to screen the large libraries of the available chemical [...]](http://q-pharm.com/wp-content/uploads/2010/07/influenza.png "Beefing up the pipeline: new leads against influenza virus identified")
Beefing up the pipeline: new leads against influenza virus identified
Posted on September 20, 2010 | No CommentsQuantum Free energy calculation software in combination with the docking tools and clustering tools to “zip” the amount of work required to screen the large libraries of the available chemical [...] -
![Recently, RecA has established itself as a potential target for the development of antibacterial drugs. The dual function of recA allows bacteria both to control the damage associated with the [...]](http://q-pharm.com/wp-content/uploads/2010/07/recAhits.png "New inhibitors of RecA (bacterial SOS response system) identified.")
New inhibitors of RecA (bacterial SOS response system) identified.
Posted on July 14, 2010 | 2 CommentsRecently, RecA has established itself as a potential target for the development of antibacterial drugs. The dual function of recA allows bacteria both to control the damage associated with the [...]